Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, Najib Dally, Abraham Avigdor, Galia Rahav, Yaniv Lustig, Shirley Shapiro Ben David, Riva Fineman, Alona Paz, Osnat Bairey, Aaron Polliack, Ilana Levy, Tamar Tadmor
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Ferrata Storti Foundation 2021-07-01
سلاسل:	Haematologica
الوصول للمادة أونلاين:	https://haematologica.org/article/view/10351
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!